Beta Bionics, Inc. (BBNX) exhibits a mixed profitability profile dominated by significant margin concerns. The current gross margin of 55.4% sits at the 6th percentile of its 10‑year historical range, indicating that the company is operating well below its long‑term norm and suggesting structural cost pressures or pricing challenges. More alarming, the net margin remains deeply negative at -73.0%, triggering a critical alert for sustained losses and underscoring an inability to translate revenue into profit after all expenses. While operating margin has stabilized in recent periods, it is still profoundly negative at -71.5% and reflects ongoing high operating expense levels relative to sales. Despite a modest year‑over‑year gross margin improvement of +0.3%, the three‑year decline of 44.6% signals a longer‑term erosion rather than a short‑term cyclical dip. The net margin’s year‑over‑year swing of +11.1% is insufficient to offset its entrenched loss position, and the massive three‑year increase in operating margin (a rise of 36,712.9%) is driven by an already extreme negative base rather than genuine operational leverage. Overall, BBNX’s margin trajectory lags far behind its historical performance and raises concerns about cash generation and financial sustainability over the next 6–18 months.

Beta Bionics exhibits an exceptionally low leverage profile, with a current debt-to-equity ratio of 0.03x—well below its 10‑year average of 0.13x and positioned at the 0th percentile of historical observations. Net debt relative to EBITDA stands at 0.3x, also beneath the decade average of 0.5x and again in the bottom percentile, indicating ample capacity to service debt even under adverse operating conditions. The company’s leverage metrics have been trending modestly downward year‑over‑year, reflecting a continued de‑leveraging path that enhances its solvency buffer for the next 12‑18 months.

Beta Bionics is experiencing a pronounced deterioration in cash generation quality, with both operating cash flow (OCF) and free cash flow (FCF) turning deeply negative this period. The OCF of -$0.1 billion represents a YoY decline of $2.652 million, while FCF worsened by $4.554 million year‑over‑year, confirming that the business is burning cash faster than it can generate from core operations and investing activities. Although short‑term liquidity metrics appear robust—current ratio at 8.66× (above the 10‑year average of 6.98×) and quick ratio at 7.96× (above its 6.62× average)—the cash ratio has slipped to 1.02× from a historical 2.02×, indicating that readily available cash is insufficient to cover current liabilities without relying on liquid assets. The combination of negative cash flows and eroding cash reserves raises concerns about the company’s ability to sustain operations without external financing in the near term.

Beta Bionics' earnings exhibit modest cash conversion, with operating cash flow covering only 70% of net income—below the 80% safety threshold and indicating that a portion of reported profit is not yet reflected in cash. While accruals are slightly less negative than the ten‑year average (‑0.068 vs ‑0.086), the ratio remains in negative territory, suggesting earnings are still being boosted by accounting adjustments rather than cash generation. The company’s stock‑based compensation (SBC) is unusually high at 16.3% of revenue, far exceeding the 10% benchmark and dwarfing its ten‑year average of 870%, which signals a significant non‑cash expense that can dilute shareholder value if not managed.